Dear Doctor - Participate in the Survey on valproic acid "A new survey has found that the use of Valproic acid is on the rise among people with epilepsy. The survey, which was conducted by the Epilepsy Foundation, found that nearly a third of respondents said they had used Valproic acid in the past year to treat their seizures. This is up from just over a fifth in a previous survey. Valproic acid is an anticonvulsant medication that is commonly used to treat epilepsy. It can be taken as a pill or liquid, and it works by reducing seizure activity in the brain. The medication is generally considered to be safe and effective, but there are some potential side effects, including drowsiness, nausea, vomiting, and weight gain.If you have epilepsy and are considering using Valproic acid to treat your seizures, talk to your doctor to see if it is the right option for you. Participate now."
1.
Examines Office-Based Transperineal Prostate Biopsies Methodology.
2.
Patients value communication skills from cancer surgeons across six key areas, according to research
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
5.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
1.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
2.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
3.
Iron Deficiency Anemia: Challenges in Diagnosis and Treatment
4.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
5.
The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation